drugset / Trial / NCT04215393
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
Non-randomizedSequentialOpen-labelOther
Summary
The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization. The second stage of this study will evaluate the effectiveness of conbercept eye drop initially.
Timeline
- Start
- 2019-07-18
- Primary completion
- 2020-04
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.1 mg/ml | Other |
| Subject | Conbercept | Protein / enzyme biologic | 0.5 mg/ml | Other |
| Subject | Conbercept | Protein / enzyme biologic | 1 mg/ml | Other |